Dr. Peter E. Clark is the associate professor of urologic surgery, a VICC member and an urologic oncologist at Vanderbilt University Medical Center. He was able to take time out of his extremely busy schedule to participate in this interview, highlighting the importance of CHTN in his research endeavors.
Dr. William E. Grizzle is Professor of Pathology, Head of the Program for Translational Research in Neoplasia, Director of Tissue Procurement and Banking Facility, Director of the Southern Division, Cooperative Human Tissue Network, Senior Scientist of the UAB Comprehensive Cancer Center; Center for Aging; Metabolic Bone Disease Research Center, and Senior Editor of Clinical Cancer Research. Dr. Grizzle was kind enough to participate in the interview, discussing the challenges of biorepositories.
Research Offers Hope for Inflammatory Bowel Disease, an interview with Steven R. Tannenbaum, Underwood-Prescott Professor of Toxicology, Professor of Chemistry, Massachusetts Institute of Technology, by Sarah Jane-Krista Feyas, CHTN Western Division at Vanderbilt University Medical Center.
"The role of the CHTN in the human subjects research program of orthopaedic surgery cannot be overestimated."
Annamarie Horan, Ph.D. (CHTN investigator since 2010)
Director, Clinical Research
Department of Orthopaedic Surgery
University of Pennsylvania
"The CHTN offers the best pricing and value, and provides tissue slides in a timely manner."
Julie Bianco (CHTN investigator since 2006)
Research Scientist
PeproTech, Inc.
"CHTN is an outstanding resource that provides high quality tissues and tissues services to the research community across the country."
J. Douglas Larigan, MBA (CHTN investigator since 1997)
Research Leader
Hoffman- La Roche
"Two RO1s and a DOD idea award that we have received in the past three years as well as three papers published in Cancer Research by our group were supported by the results derived from the CHTN tissues."
Stuart Aaronson, MD (CHTN investigator since 2007)
Associate Professor
Mount Sinai School of Medicine
"Being at the beginning of my career and without federal funding, I was fortunate to establish collaboration with CHTN which enabled me to successfully pursue my research project. Thus far, one provisional patent and two manuscripts are in preparation."
Sinisa Vukelic, Ph.D. (CHTN investigator since 2010)
Associate Professor of Mechanical Engineering
Bucknell University
"My research has been supported for 13 years by the NCI Intramural Program and for the last 8 years by two research grants from the NCI. The tissue you provide has been instrumental in over 50 of my publications related to cervical cancer."
Craig Woodworth, Ph.D. (CHTN investigator since 1990)
Professor & Chair of Biology
Department of Biology
Clarkson University
"CHTN works diligently to fulfill the specific research needs of individual investigators at a minimal cost."
David Mu, Ph.D. (CHTN investigator since 2005)
Associate Professor
Division of Experimental Pathology
Penn State University
"The data I generated using these samples not only helped me to move my research forward, but also secured two national grants, a patent application and a peer-reviewed publication for our group."
Edward Chan, MD (CHTN investigator since 2006)
Assistant Professor of Pediatrics/Ped Hem/Onc
Oncology Translational Research
Stony Brook University Medical Center
"We have found CHTN to be more responsive than NDRI, and to be competitive with fee for service commercial agencies."
Luis Garza, MD, Ph.D. (CHTN investigator since 2011)
Assistant Professor
Department of Dermatology
John Hopkins School of Medicine
"...we have found CHTN to be our only consistent and reliable source of fresh cervical tissue..."
Richard Schlegal, MD, Ph.D. (CHTN investigator since 2009)
Professor & Oscar B Hunter Chair
Department of Pathology
Georgetown University Medical School
"Prior to receiving samples from the CHTN we tried to obtain tissues from other local and commercial sources we tried. We were very pleased to find out about the CHTN because the tissues they provided were of higher quality, were much more affordable, and were often available in much larger sizes."
Brad St. Croix, Ph.D. (CHTN investigator since 2004)
Head Tumor Angiogenesis Section
National Cancer Institute - Frederick
"I would be handicapped without the CHTN and will require this resource to conduct my research forward in order to obtain a complete picture of integrative genomics."
Kamalakannan Palanichamy, MS (CHTN investigator since 2009)
Associate Professosr
Department of Radiation Oncology
The Ohio State University
"Our CHTN collaboration has been a true asset to our efforts in developing new in vitro models for cosmetic testing."
Teresa DiColandrea (CHTN investigator since 2008)
Sr. Scientist
Proctor & Gamble
"As a company that aims to accelerate the understanding of fundamental biological processes, it is imperative that we have access to the resources offered by the CHTN to do our work."
Adel Mikhail, Ph.D. (CHTN investigator since 2003)
Phylogeny
"CHTN has been a major source of tissue samples for clinical & translational research to support our NIH grants, including a $1M RO1 from the National Library of Medicine & $1M ARRA stimulus grant. It has been included in the competitive renewal of our RO1 grant as an important infrastructure supporting the proposed research on lung cancer prognosis."
Nancy Guo, Ph.D (CHTN investigator since 2007)
Associate Professor of Community Medicine
West Virginia University
Mary Babb Randolph Cancer Center
"CHTN provides an essential element of educational resource to the biorepository community."
"Without their expertise, programs such as ours would be severely impacted."
Michael McPhee, M.D. FACS
Medical Director of Surgical Oncology
ProMedica Cancer Institute
"My research work could not have been successful without the superior job that you (CHTN) and your collaborators, especially Kathy Sexton, have done and continue to do."
Manuel Perucho, Ph.D. (CHTN investigator since 1987)
Prof. & Co-Director
Tumor Development Program
Sanford Burnham Medical Research Institute
"Primary hepatocellular carcinomas and benign cirrotic liver tissue are particularly rare commodotities and the CHTN has been an invaluable resource for us in the acquisition of multiple samples of these tissues."
Marie Hanigan, PhD (CHTN investigator since 2009)
Department of Cell Biology
University of Oklahoma
"I could not have accomplished my studies without the low cost of samples from CHTN if I had to acquire tissues from other resources."
Felix Aikhionbare, Ph.D. (CHTN investigator since 2002)
"Our institution is not associated with a hospital or other source of human tissues. Consequently, much of the research we are conducting would not be possible without tissues provided by the Southern Division of the CHTN."
Barbara Parsons (CHTN investigator since 2003)
Research Microbiologist
National Center for Toxicological Research, U.S. FDA
"I can state unequivocally that without the tumor tissues provided by the CHTN our studies would not have been possible."
Jesse Martinez, Ph.D. (CHTN investigator since 2002)
Prof. of Cellular and Molecular Medicine
Arizona Cancer Center
"We could not have accomplished our validation studies at the same scale & economy if we had to acquire tissues from other resources. As our research moves forward, the CHTN will continue to be an invaluable resource for our mission to develop more effective, less toxic treatments that extend life and provide a better quality of life for patients diagnosis with chronic and life threatening disease."
Jan Schnitzer, MD (CHTN investigator since 1999)
Director
Protogenomics Research Institute for Systems Medicine (PRISM)
"The supplied tissues have led to novel discoveries about how formalin fixation occurs and has resulted in 2 patent filings this year alone. Without this resource, my group would still be years behind where we are today."
David Chafin, Ph.D. (CHTN investigator since 2009)
Manager, Systems Integration
Ventana Medical Systems, Inc.
"The samples CHTN provide are truly helping to advance cancer research and save lives."
Brian Hart (CHTN investigator since 2010)
Sr. Manager, Tissue Sample Management
Ventana Medical Systems, Inc.
"The quality and cost effectiveness of these samples has greatly facilitated the progress of our research over the past three years..."
Thea Tlsty, Ph.D. (CHTN investigator since 2008)
Department of Pathology
University of California, San Francisco
"Due to my ability to procure these tissues from CHTN, for the past two years, I have been able to generate preliminary data that has enabled me to get NCI funded grant on health disparity for (the next) five years."
"Although I have been doing breast cancer research for 15 years now and have approached many scientists and MDs for tissue, I have been only successful in obtaining them from CHTN."
Shehla Pervin, Ph.D. (CHTN investigator since 2009)
Assistant Professor
Charles Drew University of Medicine and Science
"As a pathologist, I do have IRB certification and can access samples on my own, however, I prefer the ease and convenience of emailing and requesting samples which are delivered promptly to my office or laboratory, each accompanied with brief clinical information."
Nissi Varki, MD (CHTN investigator since 1997)
Director
Histocytology & Immunohistochemistry Services
University of California, San Diego
"I have been in biomedical research for over 40 years and I have never dealt with an organization more helpful and responsive than CHTN."
Laurence McIntyre Ph.D. (CHTN investigator since 2004)
Research Director
Vector Laboratories
"Without an organization such as CHTN, scientists would have much greater difficulty testing out hypotheses requiring fresh tissue."
Warner Greene, MD, Ph.D. (CHTN investigator since 2009)
Director
The J. David Gladstone Institutes
"We greatly appreciate access to human skin samples from the CHTN. They provide a critical service for my lab and allow us to do cutting edge science that is relevant to human disease."
Wendy Havran, Ph.D. (CHTN investigator since 2007)
Professor
The Scripps Research Institute
"...we have found CHTN to be a trustworthy and indispensable source of biological materials for our research."
Paul Yaswen, Ph.D. (CHTN investigator since 2005)
Staff Scientist
Lawrence Berkely National Laboratories
